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Abstract
Background: UDP-glucuronosyltransferase 1A1 (UGT1A1) is a pivotal enzyme involved in metabolism of SN-38, the
active metabolite of irinotecan commonly used to treat metastatic colorectal cancer. We previously demonstrated
aberrant methylation of specific CpG dinucleotides in UGT1A1-negative cells, and revealed that methylation state of
the UGT1A1 5’-flanking sequence is negatively correlated with gene transcription. Interestingly, one of these CpG
dinucleotides (CpG -4) is found close to a HNF1 response element (HRE), known to be involved in activation of
UGT1A1 gene expression, and within an upstream stimulating factor (USF) binding site.
Results: Gel retardation assays revealed that methylation of CpG-4 directly affect the interaction of USF1/2 with its
cognate sequence without altering the binding for HNF1-alpha. Luciferase assays sustained a role for USF1/2 and
HNF1-alpha in UGT1A1 regulation in colon cancer cells. Based on the differential expression profiles of HNF1A gene
in colon cell lines, we also assessed whether methylation affects its expression. In agreement with the presence of
CpG islands in the HNF1A promoter, treatments of UGT1A1-negative HCT116 colon cancer cells with a DNA
methyltransferase inhibitor restore HNF1A gene expression, as observed for UGT1A1.
Conclusions: This study reveals that basal UGT1A1 expression in colon cells is positively regulated by HNF1-alpha
and USF, and negatively regulated by DNA methylation. Besides, DNA methylation of HNF1A could also play an
important role in regulating additional cellular drug metabolism and transporter pathways. This process may
contribute to determine local inactivation of drugs such as the anticancer agent SN-38 by glucuronidation and
define tumoral response.
Background
Irinotecan (CPT-11) is a topoisomerase I inhibitor and
one of the main cytotoxic agent for treatment of
advanced metastatic colorectal cancer [1-3]. In vivo,i r i -
notecan is converted to 7-ethyl-10-hydroxycamptothecin
(SN-38), by a carboxylesterase-mediated hydrolysis, a
metabolite ~1000-fold more active as topoisomerase I
inhibitor than irinotecan [4,5]. The elimination pathway
of the active metabolite SN-38 is primarily through
glucuronidation, which is mainly mediated by the UDP-
glucuronosyltransferase (UGT) 1A1 enzyme [6-8]. Low
rates of SN-38 glucuronidation in tumor sites increase
the level of the active compound that could lead to
higher sensitivity to irinotecan. In contrast, high levels
of UGT activity and expression were associated with
an increase of SN-38 resistance in colon cancer cells [9].
Therefore, the regulation of UGT1A gene expression
together with other mechanisms altering its protein
activity should be considered in tumor resistance to
SN-38.
Epigenetic regulation is a key mechanism to either
activate or silence gene transcription, and abnormal epi-
genetic regulation has been described as an important
characteristic of tumor malignancy and progression
[10,11]. Furthermore, abnormal methylation of genes is
a more common mechanism influencing gene activity
than inheritable genetic mutations [12], and might con-
fer intrinsic drug resistance to chemotherapeutic treat-
ment. More specifically, colorectal cancer (CRC) is
commonly associated with an abnormal methylation of
CpG rich site (CpG island) in promoter region of
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promoter methylation in multiple genes, referred to as
the CpG island methylator phenotype [10,13]. Hence, it
is rational to propose that abnormal epigenetic regula-
tion of SN-38-metabolizing genes would be a drug resis-
tance mechanism.
We previously demonstrated aberrant methylation of
specific CpG-rich regions in UGT1A1-negative cells
(HCT116, HCT-15, and COLO-320DM), and such
events result in complete repression of UGT1A1 tran-
scriptional activity [14]. DNA methylation may repress
transcription by sterically hindering the binding of acti-
vating transcription factors (TFs) to their recognition
sites [15-17]. Similarly, treatment with DNA methylation
inhibitors enable binding of positive TFs and lead to
gene reactivation [18]. In our previous report, treatment
with demethylating and histone deacetylase inhibitor
agents had the capacity to reverse aberrant hypermethy-
lation and to restore UGT1A1 expression in hyper-
methylated UGT1A1-negative cells HCT116, but not in
hypomethylated cells. Loss of UGT1A1 methylation was
further associated with an increase in UGT1A1 protein
levels and with an enhanced SN-38 inactivation, by
300% in HCT116 colon cancer cells [14]. In addition,
human colon cancer cells has revealed that hypomethy-
lation of the UGT1A1 5’-flanking sequence (-540 to -1)
is important for UGT1A1 transcription. More specifi-
cally, the extent of UGT1A1 promoter methylation
between CpG-1 (-4nt relative to the ATG) and -4 (-99nt
relative to the ATG) of the promoter was shown to sig-
nificantly predict UGT1A1 gene expression in colon
cancer cell lines [14]. It is proposed that DNA methyla-
tion would alter the binding affinity of some important
positive TFs.
In this report, we identified TF(s) that bind and influ-
ence transcriptional activity of UGT1A1 proximal pro-
moter and determined whether methylation of CpG
dinucleotides in this genomic region prevents binding of
positive transcription factors.
Results
USF1/2 and HNF1-alpha bind the UGT1A1 gene promoter
and activate transcription
By using a computer-based approach (MatInspector;
http://www.genomatix.de/), several putative TF binding
sites were observed in UGT1A1 5’-flanking sequence
(-540 to -1), namely NF-Y (-57 to -73), HNF1-alpha
(-79 to -95), CDX2 (-98 to -118), USF (-87 to -110) and
OCT1 (-274 to -293) binding sites encompassing CpG-1
to -5 (Figure 1). Among those TFs, HNF1-alpha, CDX2
and OCT1 have previously been shown to interact with
some UGT1A isoforms [19-25], but the interaction with
UGT1A1 was only demonstrated for HNF1-alpha [26].
Interestingly, the CpG-4 is included in the USF recogni-
tion core sequence, the CpG-3 is part of the NF-Y/PBX
binding site, and the HNF1 response element (HRE) is
found between CpG-3 and -4.
To address whether NF-Y, HNF1-alpha, CDX2, USF1/
2, and OCT1 might specifically bind to the proximal
promoter of UGT1A1, electrophoretic mobility shift
assays (EMSA) were performed using nuclear protein
extracts from HT29 cells, and synthetic double-stranded
oligonucleotides derived from the UGT1A1 promoter
sequence and containing each putative TF binding site
(see Table 1). DNA-protein complexes are formed with
all transcription factor-associated oligonucleotide
probes, except for CDX2 and PBX (Figure 2). Each spe-
cific DNA-protein complex was competed by the addi-
tion of 100-fold molar excess of either the consensus
recognition sequence or the unlabeled probe, thus pro-
viding evidence for specific binding. To further support
the identity of DNA-binding proteins, we performed
binding assays in presence of specific antibodies. The
addition of mouse monoclonal anti-USF1 and anti-USF2
led to the formation of a supershifted DNA-protein
complex (designated as S in figure 2) with the USF
response element (URE)-containing probe, likely indicat-
ing that both USF1 and USF2 might bind to UGT1A1
promoter. Similar results were observed with the specific
anti-HNF1-alpha and NF-Y antibodies, whereas the pre-
sence of anti-OCT1 antibody did not affect the forma-
tion of DNA-protein complex III with the OCT1-
specific probe. The later likely indicates that an
unknown DNA-binding protein might interact with this
UGT1A1 promoter sequence.
To investigate the functional importance of these
DNA-protein interactions, namely with USF1/2, HNF1-
alpha, NF-Y, and OCT1, upon UGT1A1 proximal pro-
moter activity, we disrupted either of their predicted
recognition sequences in a 540 bp fragment of the
Figure 1 Putative transcription factor binding sites in human UGT1A1 proximal promoter. Schematic representation of the UGT1A1 gene
sequence between positions -540 and +10 (relative to the transcription start site). Positions of CpG dinucleotides are shown. Sequences of the
putative transcription factor binding sites are boxed. The recognition core sequence for each transcription factor is underlined.
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These constructions were introduced into the pGL3-
luciferase reporter plasmid and transfected in UGT1A1-
expressing HT29 cells. UGT1A1 proximal promoter
activity was significantly attenuated by disruption of
HRE and URE (Figure 3). In contrast, mutations in the
NF-Y and OCT1 binding motifs had no effect on tran-
scriptional activity. The result for OCT1 is in accor-
dance with previous EMSA experiments. Accordingly,
these results established that HRE and URE would play
ar o l ei np o s i t i v er e g u l a t i o no ft h eUGT1A1 gene
expression.
CpG methylation at the USF response element inhibits
the formation of specific DNA-protein complex
As described above, the CpG-4 is part of the USF recog-
nition core sequence. Therefore, we may expect that
cytosine methylation at this site would hinder specific
TF interaction. On the other hand, the HRE is found
between CpG-3 and -4 dinucleotides and should
Table 1 List of oligonucleotides
Transcient transfection experiement
Transcription factor
a
OCT1 5’ GGTCTGTGGAAATACTGGCCTAATGGATCCTGAGGTTC 3’
CDX2 5’ GTGGACTGACAGCTTTTCGCCGTCACGTGACACAGTC 3’
USF 5’ GCTTTTTATAGTCAATTGACACAGTCAAAC 3’
HNF1 5’ CACAGTCAAACATGAGCTTGGTGTATCGA 3’
NF-Y 5’ CTTGGTGTATCGACCTGTTTTTGCCATAT 3’
Electrophoretic mobility shift assays
Putative TFs binding motif in UGT1A1 proximal promoter
a
OCT1 5’ GTGGAAATACTAATTTAATGGA 3’
CDX2 5’ GACTGACAGCTTTTTATAGTCA 3’
CREB/USF/SREBP1 5’ TTTTTATAGTCACGTGACACAGTC 3’
HNF1 5’ CACAGTCAAACATTAACTTG 3’
NF-Y 5’ CTTGGTGTATCGATTGGTTTTTGCCAT 3’
PBX 5’ TGTATCGATTGGTTTTTGCCATATAT 3’
Consensus oligonucleotide probes used in competition assays
a
OCT1 consensus oligo 5’ TGTCGAATGCAAATCACTAGAA 3’
CDX2 consensus oligo 5’ GTGCAATAAAACTTTATGAGTA 3’
USF consensus oligo 5’ CACCCGGTCACGTGGCCTACACC 3’
HNF1 consensus oligo 5’ CCAGGTTAATGATTAACCCA 3’
NF-Y consensus oligo 5’ AGACCGTACGTGATTGGTTAATCTCTT 3’
PBX consensus oligo 5’ CGAATTGATTGATGCACTAATTGCAG 3’
Oligonucleotide probes of the UGT1A1 promoter with CpG sites
b
CpG-4/USF 5’ AGCTTTTTATAGTCACGTGACACAGTCAAACAT 3’
CpG-4/USF-HNF1 5’ TCACGTGACACAGTCAAACATTAACTTGGT 3’
Reverse transcription (RT)-PCR
Target gene
HNF-1a Forward 5’ GGTCATGAGCTTCGTCAACC 3’
HNF-1a Reverse 5’ GCAGGAAGAGATCCGATTCC 3’
USF-1 Forward 5’ GGCAGCTGAGACGGCCTTGG 3’
USF-1 Reverse 5’ TGGCCCCCATTCTCAGTTCGGA 3’
USF-2 Forward 5’ CTGCCTCTGTGCCCCCAGGT 3’
USF-2 Reverse 5’ TTGTCCCTCCGCCTCCGCTC 3’
GAPDH Forward 5’ TTGGTATCGTGGAAGGACTCA 3’
GAPDH Reverse 5’ TGTCATCATATTTGGCAGGTTT 3’
a TF recognition core sequence is underlined.
b UGT1A1 promoter CpG sites are underlined.
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lation. To investigate this, we firstly performed EMSAs
using a double-stranded oligonucleotide probe including
the URE. The oligonucleotide has been either methy-
lated or not at the CpG-4 dinucleotide (Figure 4). Incu-
bation of in vitro translated USF1 proteins with either
methylated or unmethylated 32P-labeled probe resulted
in the formation of specific DNA-protein complexes
(identified as complex I). This indicates that 5-methylcy-
tosine did not totally prevent the USF1 protein binding.
However, the protein binding to unmethylated probe is
less competed by 100-fold excess of methylated oligonu-
cleotide than the unmethylated one, whereas binding to
methylated probe is equally competed by either methy-
l a t e do ru n m e t h y l a t e dc o l do l i g o n u c l e o t i d e .I ts u g g e s t s
that USF1 may interact with methylated DNA but have
Figure 2 Interaction of transcription factors with the UGT1A1 promoter using protein nuclear extracts of UGT1A1-expressing HT29
colon cancer cells. EMSAs were performed with 32P-end-labeled probes. Nuclear protein extracts (5 μg) from HT29 cells were pre-incubated in
the presence of either no competitor or 100-fold molar excess of cold competitor oligonucleotides (C) or consensus sequence (Cs). For
supershift assays, 2 μg of the indicated antibody (Ab) were added directly after the addition of the labeled probe. For USF assays, Ab1 and Ab2
are directed against USF1 and USF2, respectively.
Figure 3 Disruption of HNF1-alpha and USF recognition sequences decreases UGT1A1 basal expression in HT29 cells. Mutational
analysis of the putative HNF1, OCT1, USF and NF-Y binding sites in the UGT1A1 proximal promoter. Relative luciferase activity is expressed as a
fold induction over the promoterless pGL3-basic vector (set to value = 1). Columns, mean of triplicates of three independent experiments; bars,
SD; *, P < 0.05
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incubation of USF1 protein with either anti-USF1 or
anti-USF2 antibody well demonstrated that USF1 speci-
fically bind this UGT1A1 promoter sequence. The
absence of supershifted complex with anti-USF2 anti-
body denotes that antibody-induced supershifted com-
plex is not caused by a non-specific interaction with the
antibody.
In a second EMSA experiment, we examined the
interaction between USF1/2 and HNF1-alpha (from
HT29 nuclear protein extracts) with UGT1A1 promoter
sequence including both TF binding sites. We used
solely unmethylated oligonucleotide as probe, but either
unmethylated or methylated oligonucleotide as cold
competitor (Figure 5). We observed the formation of
two specific and one unspecific DNA-protein complexes.
By specific competition with HRE or URE-containing
oligonucleotide, we determined that DNA-protein com-
plex I and II are formed by HNF1-alpha and USF1/2,
respectively. We noted that solely the specific complex I
is equally competed by excess of both methylated and
unmethylated cold competitor. In contrast the complex
II, formed by USF1/2, is more competed by molar
excess of unmethylated cold competitor. The unspecific
DNA-protein complex is not competed by either com-
petitor. The positive correlation between the unspecific
complex intensity and the increase amount of competi-
tor indicates a rise in probe availability for nonspecific
DNA-binding proteins. In summary, this experiment
further demonstrated that CpG methylation impairs
DNA-binding for USF1/2 but not for HNF1-alpha, likely
because its recognition site remains unaffected by CpG
methylation in our experiment context.
Upregulation of HNF1A gene expression is observed
following treatment with the 5-Aza-dC demethylating
agent in UGT1A1-negative cells
We presented that CpG methylation might affect
UGT1A1 gene expression through alteration of cis-act-
ing elements. However, evidence supports that DNA
methylation-induced gene silencing is also caused by
inhibition of trans-acting factor gene expression. We
previously demonstrated that the UGT1A1-negative cell
line HCT116 is able to express UGT1A1 following 5-
aza-dC treatment [14]. We showed that such a gene
induction is due, at least in part, by the demethylation
of UGT1A1 promoter. Considering the importance of
HNF1-alpha and USF1/2 in UGT1A1 gene expression
and also that HCT116 cell line is known to be HNF1-
negative, we sought to determine whether the USF1 and
USF2 gene expression is influenced by the cell methyla-
tion status and whether HNF1A gene expression is
restored in 5-aza-dC-treated HCT116 hypermethylated
cells. As expected, the presence of HNF1A mRNA was
undetectable by reverse PCR in untreated HCT116 cells.
However, the 5-Aza-dC treatment induced the HNF1A
g e n ee x p r e s s i o n( F i g u r e6 ) .T h e s ed a t as u p p o r tt h a t
HNF1A is also modulated in these cells by methylation,
Figure 4 Incubation with in vitro translated USF1 protein demonstrates that methylation of CpG-4 impedes USF1 binding. EMSAs were
performed with 32P-end-labeled probes. In vitro translated USF1 proteins were pre-incubated in the presence of either no competitor or 100-
fold molar excess of cold competitor oligonucleotides (C) or consensus sequence (Cs). For supershift assay, 2 μg of the indicated antibody (Ab)
were added directly after the addition of the labeled probe. Ab1 and Ab2 are directed against USF1 and USF2, respectively. In methylated
probes, dC nucleotide is substituted by an internal methyl deoxyCytidine in CpG-4 dinucleotide.
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HNF1A -5kb promoter were predicted as CpG islands
by the CpGPlot program (Emboss) (data not shown).
On the other hand, we did not get any observable varia-
tion in both USF1 and USF2 gene expression following
treatment with 5-aza-dC in both cell lines.
Discussion
In this report, we predicted several putative TF binding
sites in UGT1A1 proximal promoter using a bioinfor-
m a t i ct o o la n dd e m o n s t r a t e db yE M S At h a tH N F 1 -
alpha, USF1/2, and NF-Y would bind to UGT1A1 proxi-
mal promoter. The influence of these TFs upon
UGT1A1 transcriptional activity was then demonstrated
by transient transfection in colon adenocarcinoma cell
line HT29, and solely HNF1-alpha and USF1/2 have
been shown to have significant impact.
Mutations in the HNF1-alpha motif resulted in a sub-
stantial reduction of UGT1A1 promoter activity in
HT29 cells. This HRE located in the human UGT1A1
promoter consists of a very well conserved half-site and
am o r ed i v e r g e n to n ew i t hr e s p e c tt ot h ec o n s e n s u s
Figure 5 Methylation of CpG-4 decreases USF1/2-associated complex stability. EMSAs were performed with 32P-end-labeled probes.
Nuclear protein extracts (5 μg) from HT29 cells were pre-incubated in the presence of either no competitor or 10-, 50-, 100-fold molar excess of
cold competitors (unmethylated and methylated) or oligonucleotides including either a consensus binding site for HNF1-alpha or USF1/2. In
methylated probes, dC nucleotide in CpG dinucleotides is substituted by an internal methyl deoxyCytidine.
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UGT1A1 promoter and rat albumin promoter [26,27].
Consistent with previous studies in mice, HNF1-alpha
proteins failed to bind (data not shown) and trans-acti-
vate the human UGT1A1 promoter when the conserved
half-site is altered (Table 1). Besides, our data indicate
that the one half of the HRE palindromic sequence is
sufficient for its recognition of the UGT1A1 promoter,
and that HNF1-alpha is critical for UGT1A1 expression.
HNF1-alpha is well-known to be involved in regula-
tion of several UGTs, including human UGT2B7,
UGT2B17, UGT1A1, UGT1A3, UGT1A4, UGT1A8,
UGT1A9, UGT1A10 and rat UGT1A7 [20,21,26,28-30].
Although the role of HNF1-alpha in the regulation of
UGT1A1 has already been studied [26], the data were
limited to transient transfections of the -617/+15
UGT1A1 promoter and its HNF1-deleted construct into
UGT1A1-negative HEK293 kidney cells. In here, we
emphasized the importance of HNF1-alpha in the regu-
lation of UGT1A1, and in contrast to previous observa-
tions, data were demonstrated in cells with a known
glucuronidation capacity.
As observed for HNF1-alpha, mutations in URE also
resulted in a drastic reduction of the promoter activity
Figure 6 Upregulation of HNF1A expression is observed following treatment with the 5-Aza-dC demethylating agent in UGT1A1-
negative HCT116 colon cancer cells. Rescue of HNF1A gene expression by 5-Aza-dC treatment of colon carcinoma cell lines. Total RNA from
HT29 and HCT116 cells were randomly converted to cDNA and specific amplification for USF1, USF2, and HNF1 mRNAs were carried out.
Expression of USF1 and USF2 mRNAs are not influenced by 5-Aza-dC treatment. GAPDH gene is used as internal control. Untreated; cells not
exposed to 5-Aza-dC.
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this TF in the regulation of UGT1A1 promoter.
Upstream stimulatory factors, USF1 and 2 are late TFs
able to interact as homo- and/or heterodimers on E
boxes of CACGTG sequence [31-34]. USFs are ubiqui-
tously expressed proteins that have been described as
positive or negative regulators of numerous genes,
including cyclin-cdk encoding genes, tumour suppressor
genes, and growth factor networks [35,36]. To our
knowledge, no interaction of USF1 or USF2 with phase
II enzymes such as the UGT family members has been
documented thus far.
While EMSA indicated that NF-Y might also bind
UGT1A1 promoter, mutations in its binding motif did
not significantly reduce the luciferase activity compared
with the wild-type construct in HT29 cells, suggesting
that basal promoter activity does not require direct
interaction of this TF. Although informative, promoter-
reporter constructs inadequately mimic the chromoso-
mal context. It is now appreciated that chromatin-asso-
ciated factors are various key determinants for specific
gene expression [37]. Accordingly, we may not rule out
that NF-Y would contribute to UGT1A1 gene expres-
sion in native cells.
The observation that URE includes a CpG dinucleo-
tide contact point, which is critical for recognition by
the USF proteins, prompted us to hypothesize that a
USF E-box element that contained 5-methylcytosine in
the CACGTG core might affect the binding for USF1/2.
EMSA using unmethylated probe resulted in the forma-
tion of an USF-UGT1A1 complex. When methylated,
URE-containing oligonucleotide competed poorly for
USF1/2 binding, showing that specific methylation of
CpG-4 dinucleotide decrease the affinity for USF1/2. It
was previously shown that methylation at the CpG site,
centrally located in the E-box motif (CACpGTG),
strongly inhibits formation of DNA-protein complex
[38,39] and negatively regulates gene expression. Single
nucleotide polymorphisms, within the E-box core motif,
also modulate gene regulation. Notably, a single G/C
base transition within the USF E-box consensus of the
thymidylate synthase gene, implicated in folate metabo-
lism, prevents USF proteins from binding to their cog-
nate sequence [40].
As we observed previously for UGT1A1 [14], data
indicate that DNA methylation is one mechanism likely
involved in the down-regulation of HNF1A gene expres-
sion in colon cells. DNA methyltransferase inhibitor
treatment of UGT1A1-negative HCT116 colon cells
restored HNF1A gene expression. 5-aza-dC-induced
gene reactivation has two distinct requirements: 1) the
reversal of promoter DNA hypermethylation, and 2) the
presence of transcriptional activators competent for acti-
vation of the target promoter. Considering that HNF1-
alpha is essential for UGT1A1 gene expression, the
methylation of HNF1A gene promoter represents a sec-
ond level of DNA methylation-mediated regulation,
which highlights the complexity of epigenetic gene regu-
lation. The modulation of HNF1A expression might also
have impact on the regulation of other genes, notably
on additional phase II enzymes including other UGTs
[20,21,26,28-30], glutathione transferase [41], and sulfo-
transferase [42].
Interestingly, the UGT1A1-associated HRE, which is
free of CpG dinucleotide, is located between CpG-3 and
-4, and we demonstrated that methylation of proximal
CpG dinucleotides is not sufficient to significantly alter
HNF1-alpha binding in vitro.H o w e v e r ,w em a yn o tr u l e
out the importance of DNA methylation in the binding
of HNF1-alpha in vivo, because such a DNA modification
induces a repressive chromatin structure, and might
restrain the accessibility of HNF1-alpha to its recognition
sequence in UGT1A1 promoter. However, we suggest
that UGT1A1 proximal promoter methylation may
directly affect transcriptional activity by suppressing the
interaction of USF1/2 with its cognate sequence.
Taken together, our results reveal that both HNF1-
alpha and USF1/2 could play an important role in acti-
vating the transcription from UGT1A1 promoter. The
interplay between HNF1-alpha and USF1/2 has been
previously shown to be implicated in the liver-specific
expression of the pyruvate kinase gene, in the regulation
of three human class I alcohol dehydrogenase genes and
in the constitutive expression of CYP1A2 [43-45]. Con-
sidering that UGT1A1-mediated glucuronidation is the
primary route of irinotecan inactivation, it was suggested
that the level of UGT1A1 expression might contribute
to the differential chemosensitivity of colon tumors
[46-48]. In a previous report, we showed that methyla-
tion of UGT1A1 promoter may conduct to reduction of
gene expression level, leading to a lower UGT1A1 glu-
curonidation activity. Accordingly, positive UGT1A1
methylation in tumors, and subsequent repression of
UGT1A1-associated metabolic pathways would be
involved in retention of active SN-38 within colon can-
cer cells. This could lead to higher sensitivity to irinote-
can. In contrast, the presence of high levels of UGT
activity and expression was identified as a characteristic
associated with a resistance phenotype to SN-38 in
colon cancer cells, as supported by a previous report [9].
Conclusions
This study reveals that basal UGT1A1 expression in
colon cells is positively regulated by sequence-specific
binding of HNF1-alpha and USF1/2, and negatively
regulated by DNA methylation of CpG-4 located in the
proximal UGT1A1 promoter. This suggests that CpG-4
methylation status might be a relevant indicator of
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quence a potential epigenetic marker of UGT1A1 gene
expression. Besides, epigenetic regulation of HNF1A
gene could also play an important role in regulating
additional cellular drug metabolism and transporter
pathways. Altogether, the epigenetic regulation of
HNF1A and UGT1A1 genes may contribute to deter-
mine local inactivation of drugs, such as the anticancer
agent SN-38 by glucuronidation and define tumoral
response to irinotecan. Further studies are required to
examine this hypothesis.
Methods
Cell culture
Colon cancer cells HT29 and HCT116 were obtained
from American Type Culture Collection (Manassas,
VA). Cells were growth in the medium recommended
by American Type Culture Collection. HT29 and
HCT116 cells were kept in McCoy’s 5A medium with
1.0 mmol/L sodium pyruvate (Sigma, Oakville, Ontario,
Canada) added with 100 IU/mL penicillin, 50 μg/mL
streptomycin, and 10% fetal bovine serum. Cells were
incubated at 37°C in a humidified incubator with 5%
CO2.
Transient transfection
The preparation of UGT1A1 promoter-luciferase repor-
ter constructs has been previously described [14]. For
transient transfections, cells were plated into 24-well
microplates at approximately 80 percent of confluence
(150,000 Cells/well) in growth medium and transfected
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. UGT1A1
promoter-luciferase reporter constructs were used at
750 ng of plasmid per well and co-transfected with 5 hg
of Renilla luciferase plasmid. Cells were harvested 48
hours after transfection and assayed for promoter activ-
i t yu s i n gt h eD u a l - L u c i f e r a se Reporter Assay System.
Luciferase activity was measured by using 40 μLo fc e l l
lysate in a 96-well plate on an LB96V microplate
luminometer.
Site-directed mutagenesis
Site-directed mutants were constructed with the The
QuickChange mutagenesis kit (Stratagene) and the
mutated oligonucleotides (Table 1). Mutations were
confirmed by DNA sequencing before subcloning into
the pGL3-Basic vector.
Expression analysis by reverse transcription (RT)-PCR
Treatments with 5-Aza-dC were done as described pre-
viously [14] and RNA from HCT116 cancer cell line
was extracted with Tri-Reagent (Molecular Research
Center, Inc., Cincinnati, OH), as described in the
manufacturer’sp r o t o c o l .R N A( 1μg) was converted to
cDNA with SuperScript II RNase H-negative (Invitro-
gen, Burlington, Ontario, Canada) using the manufac-
turer’s protocol in a 20 ul reaction volume. The
amplification reactions were carried out in a 25 ul reac-
tion volume including 1 ul of cDNA reaction, 10 pmol
of each primer (listed in table 1), 200 pmol of dNTP, 1×
Taq PCR buffer, 5% Acetamide, 0,5 unit of Taq DNA
polymerase. 35 amplification cycles were peformed as
follow: 20 sec at 95°C, 20 sec at 61°C, and 30 sec at 72°
C. A 10 μL aliquot of each reaction mixture was electro-
phoresed on a 1% agarose gel containing ethidium bro-
mide. The GAPDH gene was amplified as internal
control.
Preparation of nuclear extracts and in vitro production of
USF protein
Nuclear extracts were prepared from trypsinized cells,
centrifuged for 5 min at 800 × g and then resuspended
i n5m lo fH Bb u f f e r( 1 5m MT r i s - H C l( p H8 . 0 ) ,1 5
mM NaCl, 60 mM KCl, 0,5 mM EDTA), centrifuged at
800 × g for 5 min, resuspended in 100 μl of HB buffer
supplemented with 0.05% Triton X-100 (Sigma), and
centrifuged for 10 min at 1,000 × g, and the supernatant
was discarded. The pellet was washed with 5 ml of HB
buffer containing 0.05% Triton X-100 and 5 ml of HB
buffer. Nuclei were incubated at 4°C for 30 min in 50 μl
of HB buffer containing 360 mM KCl and centrifuged
for 5 min at 10,000 × g, and the supernatant corre-
sponding to the nuclear extract was collected. The con-
centration of protein in the extracts was determined
using the Bradford method according to the manufac-
turer’s recommendations. Human USF1 cDNA clone
was kindly provided by Dr. Roger G. Roeder and
described previously [49]. USF1 protein was synthesized
in vitro using the TNT Quick Coupled Transcription/
Translation System (Promega, Madison, Wisconsin,
USA).
Electrophoretic mobility shift assay (EMSA)
Protein-DNA interactions were carried out in a 20 ul
reaction mixture including either 5 μg crude nuclear
protein extract in (figure 2 and 5) or in vitro synthesized
USF proteins (in figure 4), 50 mM HEPES (pH 7.8), 300
mM KCl, 1% Igepal, 30% glycerol, 1 mM DTT, 0.01 μg
of poly(dI-dC), 0.05 μg of ssDNA, and 20 000 CPM of
32P-radiolabeled oligonucleotide. After incubation for
20 minutes at room temperature, the protein-DNA
complexes were resolved onto 6% non-denaturing polya-
crylamide gel electrophoresis at 4°C (when using nuclear
extracts) and at room temperature (when using in vitro
translated USF proteins). For competition experiments,
unlabeled oligonucleotides were added in the reaction
mixture at a molar excess of 100-fold (Figures 2 and 4),
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Page 9 of 11or 10 to 100-fold (figure 5). The oligonucleotides includ-
ing consensus recognition sequence for transcription
factors (Table 1) are derived from Transcruz gel shift
oligonucleotides (SantaCruz Biotechnology, CA), except
for CDX2[50] and HNF1[51]. For supershift assays, 2 μg
of a monoclonal (Biogenex, San Ramon, California,
USA) antibody to human CDX2 or polyclonal antibody
to HNF1-alpha (C-19), NF-Y (CBF-B, C-18) OCT1 (C-
21), USF1 (C-20) and USF2 (C-20) (Santa Cruz Biotech-
nology, Inc., Santa Cruz, California, USA) were added
directly after the addition of labeled probe, with the
exception of pre-incubation experiments where antibo-
dies were pre-incubated for 30 min prior to probe
addition.
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